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Introduction
The assessment of efficacy of systemic anti-tumor therapy is essential for the optimal management of cancer patients. Current assessments are accomplished with imaging procedures at defined intervals evaluated using standard (RECIST 1.1) criteria(1) with or without frequent measurement of protein humoral tumor markers. Depending on the localization of the tumor, other procedures such as ultrasound can be useful. Tumor genomic testing to guide treatment decisions continues to evolve since its introduction into clinical practice matching specific cancers with targeted therapies.
Genomic testing of representative tumor biopsies provides mutational status of known driver genes, but methods currently available are reported to be inconsistent (5) (6) (7) .
Sequential biopsies during therapy have been proposed to capture alterations in driver mutations occurring with selection pressures from systemic therapies (8) , which is often contra-indicated due to technical or safety issues, as well as, patient reluctance. As an alternative, "liquid biopsies", utilizing tumor derived cell-free DNA (cfDNA) present in plasma can be used (9) as a minimally invasive method to identify "actionable" mutations with their inherent limitations, e.g. frequencies of such mutations being only 50% or lower (10) , and conflicting results by technology (6, 7) . One hallmark of cancer biology is that most cancer cells have chromosomal instability often expressed as large physical or functional somatic gains and losses in tumor cfDNA (11) (12) (13) . This report describes a novel application of the liquid biopsy by quantifying cancer-related chromosomal instability in cfDNA, an approach minimally influenced by clonal heterogeneity, which remains a problem for targeted "actionable" genes (10) . The quantification of chromosomal instability from a liquid biopsy notably does not require any prior knowledge of individual somatic tumor mutations simplifying its use in clinical settings.
In this single-blinded study of patients with multiple solid tumor types during immunotherapy treatment, alone or in combination with systemic chemotherapy (ImmunoTx), the changes in genomic copy number instability (CNI)-score of cfDNA (13) during the first therapeutic cycles was compared with conventional humoral tumor markers, with the aim to assess the efficacy of therapy as defined by imaging based RECIST1.1 and irRECIST (14) . The primary objectives of this study were to 1) investigate the usefulness of cfDNA CNI-scores in different tumor types for early prediction of therapy efficacy and 2) determine equivalency to conventional biochemical tumor markers.
Secondary objectives were the evaluation of total cfDNA concentrations and percentage of peripheral Tregs for the same purpose.
Research. 
Materials and Methods

Study design
The study was conducted as a prospective training/validation study. After obtaining written informed consent, 56 patients with advanced cancer were included at Western Regional Medical Center, Goodyear, AZ (WRMC) with blood collection and usage for this study approved by the Western Institutional Review Board (Protocol# 20140257). The study was conducted in accordance with the Declaration of Helsinki. All patients underwent systemic treatment for their advanced cancer including imaging reviewed by board-certified radiologists. Patients were divided into a Discovery cohort consisting of the first 23 patients of which 11 were assessed as disease progression (PD) and 12 as disease controlled (DC), which includes stable disease (SD) and partial response (PR). The Validation cohort consisted of a subsequent prospective collection of 33 patients (Supplementary Tables S1   and S2 ). All patients received either standard commercially available immunotherapy 
Processing of plasma and extraction of cfDNA
Blood was collected in Cell-Free DNA BCT tubes (Streck), which inhibits plasma DNAse activity and preserve leukocyte integrity (15) and processed within 5 days. Tubes were centrifuged at 2500 x g for 10 min to separate the plasma from the peripheral blood cells.
Plasma was stored at −80°C and shipped to the central laboratory of Chronix in Göttingen, Germany. DNA was extracted from 2 ml aliquots of plasma using the Large Volume Viral Nucleic Acids Extraction Kit (Roche) according to the manufacturer's instructions but without addition of carrier RNA. An artificial spike-in DNA was added to each sample before extraction to assess extraction efficiency. The DNA was eluted into 50μL Low-TE buffer (EDTA•Na 0.05 mM, Tris 5 mM) in DNA Low Bind Tubes (Sarstedt) and stored at −20°C until sequencing library preparation.
DNA recovery quantification from plasma
For the quantification of absolute cfDNA two assays, each targeting one single copy genomic locus, were used in one ddPCR together with one assay targeting the artificial Table S3 ). Cycling conditions were initial denaturation 95°C for 10min; 40 cycles 95°C for 30sec, 55°C for 1min; final heat stabilization 98°C for 10min. The absolute cfDNA concentrations were corrected for the determined spike recovery rate and a PCR length based efficiency of 60% for the 90 bp amplicons.
Sequencing
Samples with cfDNA yields >10ng were processed using the ThruPLEX DNA-seq Kit (Rubicon Genomics) according to the manufacturer's instructions. The resulting sequencing libraries were pooled and paired-end sequenced (37bp/36bp) on a NextSeq500 (Illumina).
CNI-Score Calculation
Copy-numbers were called after mapping using BWA (16) and quality filtering in ~5.5 Mbp windows (sliding), yielding an average read coverage of 24,000-fold per bin. Reads with a mapping quality score not reaching the maximum value in BWA were censored form further analysis. After correction for GC-content and mapability using proprietary algorithms for cfDNA sequencing, the read counts were transformed into log2 ratios (17) and converted into Z-values based on Gaussian transformations vs. a normal control group (n=126). These secondary data were then subjected to a noise reducing proprietary bioinformatics pipeline using stochastic and statistic algorithms to calculate a final Z-score for each bin value to be within the dispersion of the normal control group (null hypothesis: 
TSDR Percentage
The Treg-specific demethylation region (TSDR) of FoxP3 was measured after bisulfite conversion of 500ng PBMC DNA using the EZ-DNA Methylation-Gold™ Kit (Zymo Research). Of the 12μL eluate 1µL was used for determination of methylated region, while 4 μL were used for determination of demethylated region. Each reaction contained 1x
ddPCR Supermix for probes (Bio-Rad), 0.75µmol/L of each primer, and 0.25µmol/L of the respective probe (Supplementary Table S3 ) in a total reaction volume of 20 µL. Droplets were read in the QX100™ or QX200™ Droplet Digital™ PCR System (Bio-Rad) and analyzed using the embedded Quantasoft software. Results were expressed as percent copies TSDR of total FoxP3 in a subset of 29 patients.
Results
All 56 study patients with metastatic cancer had plasma samples collected prior to initiation of ImmunoTx for up to six cycles of treatment. Five patients were censored from further analysis due to low CNI-scores at baseline (two melanoma in the Discovery cohort, two renal and one pancreatic cancer in the Validation cohort). Elevated CNI-scores prior to therapy were seen in the 51 evaluable patients (91%; CI:82-97%), when compared to the Figure 2 TuM biomarkers (CEA, CA19-9, CA15-3, CA-125 and/or βHCG) were available in 29 patients prior to and during therapy at the identical blood raw time points as cfDNA. To assess the correlation with outcome, the direction of the concentration under treatment was estimated (rising or falling prior to cycle 2 and cycle 3 time points) and compared with response outcome. There was no consistency (non-predictive) in the direction of TuM in 14 of 29 patients at the early pre-cycle 2 time point (accuracy: 52%, CI:35-68%; p=0.57).
As shown in Figure 3 , a similar lack of predictive accuracy was found for total cfDNA (accuracy: 52%, CI:35-68%; p=0.54). In contrast, CNI-score direction showed a significant correlation with outcome with only four patients categorized incorrectly (accuracy: 86%, CI: 71-95%; p<0.0001). For samples before cycle 3, there was still no significant correlation for TuM (accuracy: 68%, CI:51-82%; p=0.07) or total cfDNA (accuracy: 57%, CI:40-73%; p > 0.27). In contrast, correlation with CNI-score (accuracy: 82%, CI:66-93%; p<0.001) was highly significant (Supplementary Figure S2) . 
90% in our validation group. We have seen similar effects for cytotoxic chemotherapy (24) .
These data justify prospective studies in specific cancer cohorts with defined approved treatment to validate the apparent universality of the CNI method for quantifying chromosomal instability.
The evaluation of efficacy of ImmunoTx is still a critical endeavor and has several constraints, such as pseudo-tumor progression from delayed imaging and intra-tumor inflammatory responses. Given the high costs of these therapies, early guidance as to whether a patient might benefit has not only a potential financial impact, but also a medical advantage to change therapy sooner, if it is not going to be effective or the therapy might lead to hyper-progression(4). In our series, we observed six cases of hyperprogression (examples are given in Figure 4 and Supplementary Figure S3 and S4), and five of these cases were predicted to have PD by the CNI-score at a significantly earlier time (~6 to 9 weeks) than with routine practice of imaging assessment. We also observed one case (#13-38-044) of pseudo-tumor progression(2,3) by imaging (see Figure 5 and Supplementary Figure S5 ) with an initial increase in CA-125, and at each CNI time point, there was a decline consistent with prediction for a response to ImmunoTx.
The decrease in circulating Treg could be interpreted as a general activation sign of the immune system, whereas other factors such as the tumor microenvironment and dendritic cell activation play critical roles (25) scores, which might be due to location, vasculature, or immune phenotype and merits further investigation. All other solid tumor types investigated in this work showed a uniform behavior for response outcome with ImmunoTx. Limitations due to low release of tumor DNA into the bloodstream will counteract any cfDNA method and most likely any bloodborn analytic. Also tumors with only few or copy-number neutral genomic alterations will be challenging, although such seem rare, based on the data presented herein.
The other primary objective was to compare the CNI-score with conventional tumor markers. Interestingly and noteworthy, the biochemical TuM were found to be very unreliable under therapy, when their direction was compared with outcome. This is well in line with the overall cautious recommendations made for their use in therapy monitoring (26, 27) . The comparison revealed that CNI-scores in plasma outperformed TuM substantially.
Increased total cfDNA concentrations have been shown in cancer (reviewed in (28)), and proposed for therapy monitoring (29) (30) (31) . . We could not establish any substantial predictive value for outcome, which is consistent with other recent literature (32, 33) . Figure 4 Research. 
